Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD

Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

Trifilieff, Alexandre (Ed.)

2014, VII, 146 p. 41 illus., 21 illus. in color.

A product of Springer Basel
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$149.00

(net) price for USA

ISBN 978-3-0348-0709-8

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$189.00

(net) price for USA

ISBN 978-3-0348-0708-1

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Summarizes preclinical and clinical data
  • A valuable source of information for scientists and clinicians
  • Contemporary monograph on the pharmacotherapy of COPD

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Content Level » Research

Keywords » Asthma - Beta-2-Agonists - Bronchitis - Bronchodilatator - Lung function

Related subjects » Internal Medicine - Pharmacology & Toxicology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Pharmacology / Toxicology.